(3R,4S,5S,6R)-2-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:155161

Synonyms

D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranose
Glc(?1-4)Glc(?1-4)Glc(?1-4)Glc(?1-4)Glc(?1-4)Glc(?1-4)Glc(?1-4)Glc
WURCS=2.0/1,8,7/[a2122h-1x_1-5]/1-1-1-1-1-1-1-1/a4-b1_b4-c1_c4-d1_d4-e1_e4-f1_f4-g1_g4-h1

Definition

References

GlyGen:G94542HF
GlyTouCan:G94542HF

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3R,4S,5S,6R)-2-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (3R,4S,5S,6R)-2-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (3R,4S,5S,6R)-2-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (3R,4S,5S,6R)-2-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-6-[(2R,3S,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model